U.S. Medical Cannabis Market Size and Forecast, By Usage, By Consumption, By State, and Trend Analysis, 2014-2024

  • ID: 4429467
  • Report
  • Region: United States
  • 60 pages
  • Hexa Research
1 of 4

FEATURED COMPANIES

  • American Cannabis
  • Cannabis Sativa, Inc.
  • Canopy Growth Corporation
  • GBSciences, Inc
  • Greengro Technologies
  • Medical Marijuana Inc.
  • MORE
"U.S. Medical Cannabis Market Size and Forecast, By Usage (Chronic Pain, Arthritis, Migraine, Cancer), By Consumption (Solid Edibles, Inhalation, Liquid Edibles, Topical), By State (California, Colorado, Washington, Arizona, Michigan), and Trend Analysis, 2014-2024"

The U.S. medical cannabis market is expected to be valued at USD 19.48 billion by 2024, driven by its numerous medical benefits particularly by patients suffering from cancer, chronic pain and diabetes. Favorable regulatory environment across numerous states including California and Colorado is expected to fuel the growth of the market over the next few years.

Medical Marijuana Regulation and Safety Act implemented in 2015 permits the cultivation and use of cannabis dispensaries at the state and local level which has been one of key drivers to fuel the U.S market. The rising number of states receiving approval to utilize cannabis for consumption in medical cases is expected to be one of the crucial factors to upsurge the demand for medical marijuana over the forecast period.

Over the past few decades, there have been several controversies surrounding legalization of cannabis for medical purposes; however, increasing signs of medical benefits received from the consumption of cannabis has resulted in the herb being legalized across various states in the nation. The industry is expected to witness significant growth during the forecast period owing to greater consumer acceptance along with an increasing number of companies entering the market.

The symptoms and conditions that can be treated by the herb include cancer, arthritis, epilepsy, nausea, pain Alzheimer’s disease, anorexia, AIDS, HIV, glaucoma, cachexia, Crohn’s disease, migraines, and multiple sclerosis. Chronic pain accounted for 46% of the U.S. cannabis medical market share in 2016. The ability of medical marijuana to curb pain is expected to gain popularity among patients diagnosed with chronic illnesses and pain.

In 2016, solid edibles segment dominated the U.S market generating revenues worth USD 2.47 billion and is expected to continue dominating the industry over the forecast period. The future product innovation and potential growth are substantial owing to continuous development from the consumption of cannabis infused products owing to their numerous applications including lotions, bath salts, shampoo, lip balm, toothpaste, coffee pods, baked brownies cookies, candy, confectioneries, beverages, vinegar and oils.

California is known to be the first state in U.S. that legalized cannabis for medical purpose. In 2016, California recorded the highest revenue generation and is expected to grow at a CAGR of 13% over the projected period. Over the next few years, more number of state governments are expected to legalize cannabis owing to its numerous benefits which will fuel its growth over the projected period.

PLEASE NOTE: This report will be dispatched approximately 1-2 business days after the confirmation of payment.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • American Cannabis
  • Cannabis Sativa, Inc.
  • Canopy Growth Corporation
  • GBSciences, Inc
  • Greengro Technologies
  • Medical Marijuana Inc.
  • MORE
Chapter 1. Market Summary
1.1. Market trends & movement

Chapter 2. U.S. Medical Cannabis Market Trends: Drivers & Opportunities
2.1. Introduction
2.2. Key industry trends
2.3. Market drivers
2.4. Market restraints
2.5. Value chain analysis
2.6. Porter's Five Forces analysis
2.7. SWOT

Chapter 3. U.S. Medical Cannabis Market Trends, By Usage
3.1. U.S. Medical Cannabis market movement, by usage, 2016 & 2024
3.1.1. Chronic Pain
3.1.1.1. Market estimates and forecast, 2014-2024 (USD Million)
3.1.2. Arthritis
3.1.2.1. Market estimates and forecast, 2014-2024 (USD Million)
3.1.3. Migraine
3.1.3.1. Market estimates and forecast, 2014-2024 (USD Million)
3.1.4. Cancer
3.1.4.1. Market estimates and forecast, 2014-2024 (USD Million)
3.1.5. Others
3.1.5.1. Market estimates and forecast, 2014-2024 (USD Million)

Chapter 4. U.S. Medical Cannabis Market Trends, By Consumption
4.1. U.S. Medical Cannabis market movement, by consumption, 2016 & 2024
4.1.1. Solid edibles
4.1.1.1. Market estimates and forecast, 2014-2024 (USD Million)
4.1.2. Inhalation
4.1.2.1. Market estimates and forecast, 2014-2024 (USD Million)
4.1.3. Liquid edibles
4.1.3.1. Market estimates and forecast, 2014-2024 (USD Million)
4.1.4. Topical
4.1.4.1. Market estimates and forecast, 2014-2024 (USD Million)

Chapter 5. U.S. Medical Cannabis Market Trends, By State
5.1. U.S. Medical Cannabis market movement, by state, 2016 & 2024
5.1.1. California
5.1.1.1. Market estimates and forecast, 2014-2024 (USD Million)
5.1.2. Colorado
5.1.2.1. Market estimates and forecast, 2014-2024 (USD Million)
5.1.3. Washington
5.1.3.1. Market estimates and forecast, 2014-2024 (USD Million)
5.1.4. Arizona
5.1.4.1. Market estimates and forecast, 2014-2024 (USD Million)
5.1.5. Michigan
5.1.5.1. Market estimates and forecast, 2014-2024 (USD Million)

Chapter 6. Competitive Landscape
6.1. Competitive landscape analysis, 2016
6.2. Strategic framework
6.3. Potential customer base concentration
6.4. Company market positioning
6.5. Company profiles
6.5.1. American Cannabis
6.5.1.1. Company Overview
6.5.1.2. Product Benchmarking
6.5.1.3. Financial Performance
6.5.1.4. Recent Initiatives
6.5.2. Canopy Growth Corporation
6.5.2.1. Company Overview
6.5.2.2. Product Benchmarking
6.5.2.3. Financial Performance
6.5.2.4. Recent Initiatives
6.5.3. Greengro Technologies
6.5.3.1. Company Overview
6.5.3.2. Product Benchmarking
6.5.3.3. Financial Performance
6.5.3.4. Recent Initiatives
6.5.4. Medical Marijuana Inc.
6.5.4.1. Company Overview
6.5.4.2. Product Benchmarking
6.5.4.3. Financial Performance
6.5.4.4. Recent Initiatives
6.5.5. United Cannabis
6.5.5.1. Company Overview
6.5.5.2. Product Benchmarking
6.5.5.3. Financial Performance
6.5.5.4. Recent Initiatives
6.5.6. Terra Tech Corp.
6.5.6.1. Company Overview
6.5.6.2. Product Benchmarking
6.5.6.3. Financial Performance
6.5.6.4. Recent Initiatives
6.5.7. Mentor Capital, Inc
6.5.7.1. Company Overview
6.5.7.2. Product Benchmarking
6.5.7.3. Financial Performance
6.5.7.4. Recent Initiatives
6.5.8. Cannabis Sativa, Inc.
6.5.8.1. Company Overview
6.5.8.2. Product Benchmarking
6.5.8.3. Financial Performance
6.5.8.4. Recent Initiatives
6.5.9. GBSciences, Inc
6.5.9.1. Company Overview
6.5.9.2. Product Benchmarking
6.5.9.3. Financial Performance
6.5.9.4. Recent Initiatives
6.5.10. The Green Solution.
6.5.10.1. Company Overview
6.5.10.2. Product Benchmarking
6.5.10.3. Financial Performance
6.5.10.4. Recent Initiatives
6.5.11. List of other vendors

Chapter 7. Methodology and Scope
7.1. Research methodology
7.2. Research Scope & Assumptions
7.3. List of data sources

*Full List of Tables & Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • American Cannabis
  • Canopy Growth Corporation
  • Greengro Technologies
  • Medical Marijuana Inc.
  • United Cannabis
  • Terra Tech Corp.
  • Mentor Capital, Inc
  • Cannabis Sativa, Inc.
  • GBSciences, Inc
  • The Green Solution.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll